Post by Harbour BioMed

Recently, a jury in the U.S. District Court for the District of Delaware returned a verdict in favour of Harbour BioMed in our patent infringement lawsuit against Amgen Inc. and Teneobio, Inc. The case, originally filed in 2021 by Harbour Antibodies (a member of the Harbour BioMed group), asserted that Amgen infringed patents protecting the Company’s antibody discovery platform, a groundbreaking invention made by Professor Frank Grosveld, a founder of Harbour Antibodies, (each, “Grosveld Patent”). As one of the most influential intellectual property disputes in the global antibody technology field, this case has drawn significant industry attention since it was filed. After a jury trial beginning June 8, 2026, the jury found: 🔹Amgen infringed Grosveld Patent; 🔹The infringement was willful; 🔹Grosveld Patent is valid; and 🔹Harbour is entitled to $20,203,704 in damages—the full amount requested. The finding of willful infringement also allows us to petition the court to treble the award, potentially increasing it to up to $60.6 million. This outcome validates the strength of our proprietary transgenic rodent technology and our commitment to protecting scientific innovation. Looking ahead, we will continue to enforce our broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case—while also remaining committed to protecting our intellectual property on multiple fronts. Learn more about this news: https://lnkd.in/gmVApKB9 #Patent #Biotech #Innovation #AntibodyTherapeutics